Even people who achieve the treatment goals with the new obesity pharmacotherapies might decide to undergo bariatric surgery to support long-term weight maintenance because either they experience weight regain on the medication or they do not have long-term access to obesity pharmacotherapy, or they prefer not to take obesity pharmacotherapy lifelong
Contiene : Agua, carnitina
Doug Long, IQVIAs vice president of industry relations, caught up with Pharma Commerce at the Asembia AXS25 Summit 5 to discuss exactly that
Our medical weight loss program combines personalized guidance, clinical supervision, and advanced GLP-1 therapy to help you take control of your health and confidence
7 biggest news story of 2025: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), in widespread use to treat diabetes and obesity, have also demonstrated off-label benefits for a multitude of conditions, including cardiovascular disease, hypertension, Parkinsons, Alzheimers and some addictive disorders